Albert C Ludolph

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4981614/publications.pdf

Version: 2024-02-01

338	16,825	18887 64	26792 111
papers	citations	h-index	g-index

352	352	352	17739
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Caregiversâ€™ divergent perspectives on patientsâ€™ well-being and attitudes towards hastened death in Germany, Poland and Sweden. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 252-262.	1.1	2
2	Neuropsychological deficits have only limited impact on psychological well-being in amyotrophic lateral sclerosis. Journal of Neurology, 2022, 269, 1369-1374.	1.8	5
3	FRONTotemporal dementia Incidence European Research Studyâ€"FRONTIERS: Rationale and design. Alzheimer's and Dementia, 2022, 18, 498-506.	0.4	12
4	Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 68-74.	0.9	39
5	De novo mutations in SOD1 are a cause of ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 201-206.	0.9	19
6	FUS mutations dominate TBK1 mutations in FUS/TBK1 double-mutant ALS/FTD pedigrees. Neurogenetics, 2022, 23, 59-65.	0.7	3
7	The spectrum and differential diagnosis of acquired ocular motor nerve palsies: a clinical study of 502 patients. Journal of Neurology, 2022, 269, 2140-2148.	1.8	4
8	Involvement of cortico-efferent tracts in flail arm syndrome: a tract-of-interest-based DTI study. Journal of Neurology, 2022, 269, 2619-2626.	1.8	5
9	Clinicoanatomical substrates of selfish behaviour in amyotrophic lateral sclerosis â€“ An observational cohort study. Cortex, 2022, 146, 261-270.	1.1	8
10	Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurology, 2022, 79, 121.	4.5	78
11	Fat-rich versus carbohydrate-rich nutrition in ALS: a randomised controlled study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 298-302.	0.9	12
12	HARM revisited: Etiology of subarachnoid hyperintensities in brain FLAIR MRI. International Journal of Stroke, 2022, 17, 1121-1128.	2.9	2
13	Blood Î²-Synuclein and Neurofilament Light Chain During the Course of Prion Disease. Neurology, 2022, , 10.1212/WNL.0000000000200002.	1.5	11
14	Pharyngeal electrical stimulation in amyotrophic lateral sclerosis: a pilot study. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642110683.	1.5	5
15	J wave syndromes in patients with spinal and bulbar muscular atrophy. Journal of Neurology, 2022, 269, 3690-3699.	1.8	4
16	Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2022, 9, 351-362.	1.7	5
17	Fast Maturation of Splenic Dendritic Cells Upon TBI Is Associated With FLT3/FLT3L Signaling. Frontiers in Immunology, 2022, 13, 824459.	2.2	2
18	Serum <scp>Betaâ€Synuclein</scp> Is Higher in Down Syndrome and Precedes Rise of <scp>pTau181</scp>. Annals of Neurology, 2022, 92, 6-10.	2.8	9

#	Article	IF	Citations
19	Body fat compartment determination by encoderâ€“decoder convolutional neural network: application to amyotrophic lateral sclerosis. Scientific Reports, 2022, 12, 5513.	1.6	1
20	Heterozygous DHTKD1 Variants in Two European Cohorts of Amyotrophic Lateral Sclerosis Patients. Genes, 2022, 13, 84.	1.0	6
21	Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting. PLoS ONE, 2022, 17, e0266906.	1.1	7
22	Methylome analysis of ALS patients and presymptomatic mutation carriers in blood cells. Neurobiology of Aging, 2022, 116, 16-24.	1.5	8
23	Digital Scientific Platform for Independent Content in Neurology: Rigorous Quality Guideline Development and Implementation. Interactive Journal of Medical Research, 2022, 11, e35698.	0.6	0
24	Serum GFAP differentiates Alzheimerâ€™s disease from frontotemporal dementia and predicts MCI-to-dementia conversion. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 659-667.	0.9	21
25	Use and subjective experience of the impact of motor-assisted movement exercisers in people with amyotrophic lateral sclerosis: a multicenter observational study. Scientific Reports, 2022, 12, .	1.6	2
26	Relaxation-weighted ²³Na magnetic resonance imaging maps regional patterns of abnormal sodium concentrations in amyotrophic lateral sclerosis. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211094.	1.1	4
27	Fast versus slow disease progression in amyotrophic lateral sclerosisâ€“clinical and genetic factors at the edges of the survival spectrum. Neurobiology of Aging, 2022, 119, 117-126.	1.5	5
28	Cerebrospinal Fluid Levels of Prodynorphinâ€Derived Peptides are Decreased in Huntington's Disease. Movement Disorders, 2021, 36, 492-497.	2.2	12
29	Seizures associated with antibodies against cell surface antigens are acute symptomatic and not indicative of epilepsy: insights from long-term data. Journal of Neurology, 2021, 268, 1059-1069.	1.8	20
30	Hemizygous deletion of Tbk1 worsens neuromuscular junction pathology in TDP-43 transgenic mice. Experimental Neurology, 2021, 335, 113496.	2.0	15
31	Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199890.	1.5	14
32	Differential effect of ethanol intoxication on peripheral markers of cerebral injury in murine blunt traumatic brain injury. Burns and Trauma, 2021, 9, tkab027.	2.3	4
33	The value of qualitative muscle MRI in the diagnostic procedures of myopathies: a biopsy-controlled study in 191 patients. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642098525.	1.5	5
34	Segmental involvement of the corpus callosum inC9orf72-associated ALS: a tract of interest-based DTI study. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110029.	1.1	13
35	Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA). Orphanet Journal of Rare Diseases, 2021, 16, 10.	1.2	13
36	MRI as a first-line imaging modality in acute ischemic stroke: a sustainable concept. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110303.	1.5	6

#	Article	IF	Citations
37	Phelan McDermid Syndrome: Multiple Sclerosis as a Rare but Treatable Cause for Regressionâ€"A Case Report. International Journal of Molecular Sciences, 2021, 22, 2311.	1.8	4
38	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 276-286.	1.1	14
39	Comparison of MRI-based and PET-based image pre-processing for quantification of 11C-PBB3 uptake in human brain. Zeitschrift Fur Medizinische Physik, 2021, 31, 37-47.	0.6	1
40	A Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany. Brain Sciences, 2021, 11, 372.	1.1	15
41	Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. Annals of Clinical and Translational Neurology, 2021, 8, 1049-1063.	1.7	29
42	Diagnostic value of video-oculography in progressive supranuclear palsy: a controlled study in 100 patients. Journal of Neurology, 2021, 268, 3467-3475.	1.8	5
43	Eye movement alterations in presymptomatic C9orf72 expansion gene carriers. Journal of Neurology, 2021, 268, 3390-3399.	1.8	9
44	Quality of Life in SMA Patients Under Treatment With Nusinersen. Frontiers in Neurology, 2021, 12, 626787.	1.1	9
45	Protein Binding Partners of Dysregulated miRNAs in Parkinsonâ€™s Disease Serum. Cells, 2021, 10, 791.	1.8	11
46	A serum microRNA sequence reveals fragile X protein pathology in amyotrophic lateral sclerosis. Brain, 2021, 144, 1214-1229.	3.7	8
47	Altered perivascular fibroblast activity precedes ALS disease onset. Nature Medicine, 2021, 27, 640-646.	15.2	69
48	The differential diagnostic value of a battery of oculomotor evaluation in Parkinson's Disease and Multiple System Atrophy. Brain and Behavior, 2021, 11, e02184.	1.0	13
49	Disruption of orbitofrontal-hypothalamic projections in a murine ALS model and in human patients. Translational Neurodegeneration, 2021, 10, 17.	3.6	15
50	Cytoplasmic FUS triggers early behavioral alterations linked to cortical neuronal hyperactivity and inhibitory synaptic defects. Nature Communications, 2021, 12, 3028.	5.8	28
51	Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen. European Journal of Neurology, 2021, 28, 2582-2595.	1.7	16
52	Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregiversâ€™ Lives. Brain Sciences, 2021, 11, 748.	1.1	30
53	Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia. Cortex, 2021, 140, 66-79.	1.1	10
54	Administration of Riluzole Oral Suspension During the Different Stages of Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2021, 12, 633854.	1.1	4

#	Article	IF	Citations
55	Acute TBK1/IKK-Îµ Inhibition Enhances the Generation of Disease-Associated Microglia-Like Phenotype Upon Cortical Stab-Wound Injury. Frontiers in Aging Neuroscience, 2021, 13, 684171.	1.7	11
56	Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. Translational Neurodegeneration, 2021, 10, 31.	3.6	18
57	Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder. Journal of Psychiatric Research, 2021, 144, 54-58.	1.5	34
58	Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110303.	1.5	28
59	Feature selection from magnetic resonance imaging data in ALS: a systematic review. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110510.	1.1	15
60	Clinico-genetic findings in 509 frontotemporal dementia patients. Molecular Psychiatry, 2021, 26, 5824-5832.	4.1	23
61	Phenotyping of the thoracic-onset variant of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, , jnnp-2021-326712.	0.9	4
62	Life Course of Physical Activity and Risk and Prognosis of Amyotrophic Lateral Sclerosis in a German ALS Registry. Neurology, 2021, 97, 10.1212/WNL.0000000000012829.	1.5	10
63	A natural history comparison of SOD1-mutant patients with amyotrophic lateral sclerosis between Chinese and German populations. Translational Neurodegeneration, 2021, 10, 42.	3.6	9
64	Segmental Alterations of the Corpus Callosum in Progressive Supranuclear Palsy: A Multiparametric Magnetic Resonance Imaging Study. Frontiers in Aging Neuroscience, 2021, 13, 720634.	1.7	2
65	Multiparametric Microstructural MRI and Machine Learning Classification Yields High Diagnostic Accuracy in Amyotrophic Lateral Sclerosis: Proof of Concept. Frontiers in Neurology, 2021, 12, 745475.	1.1	11
66	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	9.4	223
67	Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. Journal of Neurology, 2020, 267, 36-44.	1.8	47
68	Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathologica, 2020, 139, 119-134.	3.9	73
69	In vivo tracking of TDP43 in ALS: cognition as a new biomarker for brain pathology. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 125-125.	0.9	4
70	SQSTM1/p62 variants in 486 patients with familial ALS from Germany and Sweden. Neurobiology of Aging, 2020, 87, 139.e9-139.e15.	1.5	23
71	Effect of Highâ€Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. Annals of Neurology, 2020, 87, 206-216.	2.8	105
72	Severe white matter damage inSHANK3deficiency: a human and translational study. Annals of Clinical and Translational Neurology, 2020, 7, 46-58.	1.7	15

#	Article	IF	Citations
73	Commentary: Effects of ALS-associated TANK binding kinase 1 mutations on protein-protein interactions and kinase activity. Frontiers in Neuroscience, 2020, 14, 551006.	1.4	0
74	Haploinsufficiency of TANK-binding kinase 1 prepones age-associated neuroinflammatory changes without causing motor neuron degeneration in aged mice. Brain Communications, 2020, 2, fcaa133.	1.5	9
75	Pattern of paresis in ALS is consistent with the physiology of the corticomotoneuronal projections to different muscle groups. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 991-998.	0.9	24
76	Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1007-1009.	0.9	36
77	The intrinsically restructured fovea is correlated with contrast sensitivity loss in Parkinsonâ€™s disease. Journal of Neural Transmission, 2020, 127, 1275-1283.	1.4	2
78	Dipeptide repeat protein and TDP-43 pathology along the hypothalamicâ€“pituitary axis in C9orf72 and non-C9orf72 ALS and FTLD-TDP cases. Acta Neuropathologica, 2020, 140, 777-781.	3.9	8
79	Deficits in verbal fluency in presymptomatic C9orf72 mutation gene carriersâ€”a developmental disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1195-1200.	0.9	42
80	Gene specific therapies â€“ the next therapeutic milestone in neurology. Neurological Research and Practice, 2020, 2, 25.	1.0	14
81	Quantitative mass spectrometry suggests betaâ€synuclein as promising blood marker for synaptic degeneration in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e040246.	0.4	0
82	The m.9143T>C Variant: Recurrent Infections and Immunodeficiency as an Extension of the Phenotypic Spectrum in MT-ATP6 Mutations?. Diseases (Basel, Switzerland), 2020, 8, 19.	1.0	1
83	A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 452-458.	1.1	15
84	In vivo histopathological staging in C9orf72-associated ALS: A tract of interest DTI study. NeuroImage: Clinical, 2020, 27, 102298.	1.4	20
85	Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurology, The, 2020, 19, 317-325.	4.9	196
86	Focal alterations of the callosal area III in primary lateral sclerosis: An MRI planimetry and texture analysis. NeuroImage: Clinical, 2020, 26, 102223.	1.4	13
87	Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 503-511.	0.9	33
88	Histological correlates of postmortem ultra-high-resolution single-section MRI in cortical cerebral microinfarcts. Acta Neuropathologica Communications, 2020, 8, 33.	2.4	16
89	Identification of a potential non-coding RNA biomarker signature for amyotrophic lateral sclerosis. Brain Communications, 2020, 2, fcaa053.	1.5	34
90	Disease progression but not physical state per se determines mental wellbeing in ALS. Journal of Neurology, 2020, 267, 3593-3601.	1.8	13

#	Article	IF	Citations
91	Camptocormia as a Novel Phenotype in a Heterozygous POLG2 Mutation. Diagnostics, 2020, 10, 68.	1.3	5
92	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimerâ€™s Disease. Journal of Proteome Research, 2020, 19, 1310-1318.	1.8	43
93	Fabry Disease With Concomitant Lewy Body Disease. Journal of Neuropathology and Experimental Neurology, 2020, 79, 378-392.	0.9	16
94	CSF SerpinA1 in Creutzfeldtâ€“Jakob disease and frontotemporal lobar degeneration. Annals of Clinical and Translational Neurology, 2020, 7, 191-199.	1.7	16
95	Association of Insulin-like Growth Factor 1 Concentrations with Risk for and Prognosis of Amyotrophic Lateral Sclerosis â€“ Results from the ALS Registry Swabia. Scientific Reports, 2020, 10, 736.	1.6	19
96	Sporadic inclusion body myositis: no specific cardiac involvement in cardiac magnetic resonance tomography. Journal of Neurology, 2020, 267, 1407-1413.	1.8	4
97	Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 783-785.	0.9	15
98	Multiplexed chemogenetics in astrocytes and motoneurons restore bloodâ€“spinal cord barrier in ALS. Life Science Alliance, 2020, 3, e201900571.	1.3	18
99	Parvalbumin Interneurons Shape Neuronal Vulnerability in Blunt TBI. Cerebral Cortex, 2019, 29, 2701-2715.	1.6	18
100	Morphological MRI investigations of the hypothalamus in 232 individuals with Parkinson's disease. Movement Disorders, 2019, 34, 1566-1570.	2.2	9
101	Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis. Acta Neuropathologica Communications, 2019, 7, 114.	2.4	11
102	Increased Immune Activation by Pathologic Î±â€Synuclein in Parkinson's Disease. Annals of Neurology, 2019, 86, 593-606.	2.8	95
103	Differential diagnosis of peripheral facial nerve palsy: a retrospective clinical, MRI and CSF-based study. Journal of Neurology, 2019, 266, 2488-2494.	1.8	39
104	Olfactory screening of Parkinsonâ€™s Disease patients and healthy subjects in China and Germany: A study of cross-cultural adaptation of the Sniffinâ€™ Sticks 12-identification test. PLoS ONE, 2019, 14, e0224331.	1.1	14
105	Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2019, 6, 2384-2394.	1.7	49
106	Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. Brain, 2019, 142, e67-e67.	3.7	1
107	Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice. Journal of Experimental Medicine, 2019, 216, 267-278.	4.2	57
108	The same cortico-efferent tract involvement in progressive bulbar palsy and in â€˜classicalâ€™ ALS: A tract of interest-based MRI study. NeuroImage: Clinical, 2019, 24, 101979.	1.4	9

#	Article	IF	Citations
109	Longitudinal diffusion tensor magnetic resonance imaging analysis at the cohort level reveals disturbed cortical and callosal microstructure with spared corticospinal tract in the TDP-43G298S ALS mouse model. Translational Neurodegeneration, 2019, 8, 27.	3.6	13
110	Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimerâ€™s Disease and Correlates with Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 67, 481-488.	1.2	171
111	A biallelic mutation linksMYORGto autosomal-recessive primary familial brain calcification. Brain, 2019, 142, e4-e4.	3.7	17
112	Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984605.	1.5	41
113	STAT6 mediates the effect of ethanol on neuroinflammatory response in TBI. Brain, Behavior, and Immunity, 2019, 81, 228-246.	2.0	31
114	ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2019, 10, 293.	1.1	54
115	Genomeâ€wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsy. Movement Disorders, 2019, 34, 1049-1059.	2.2	24
116	Can we turn mice into men?. Journal of Neurochemistry, 2019, 149, 168-169.	2.1	0
117	CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort. Frontiers in Immunology, 2019, 10, 641.	2.2	34
118	Ethical Principles in Patient-Centered Medical Care to Support Quality of Life in Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2019, 10, 259.	1.1	9
119	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. Cortex, 2019, 117, 33-40.	1.1	17
120	Exome array analysis of rare and low frequency variants in amyotrophic lateral sclerosis. Scientific Reports, 2019, 9, 5931.	1.6	16
121	Retinoic acid worsens ATG10-dependent autophagy impairment in TBK1-mutant hiPSC-derived motoneurons through SQSTM1/p62 accumulation. Autophagy, 2019, 15, 1719-1737.	4.3	40
122	Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. Journal of Psychiatric Research, 2019, 113, 137-140.	1.5	81
123	Juxtacortical lesions are associated with seizures in cerebral small vessel disease. Journal of Neurology, 2019, 266, 1230-1235.	1.8	7
124	Combined cerebral atrophy score in Huntington's disease based on atlas-based MRI volumetry: Sample size calculations for clinical trials. Parkinsonism and Related Disorders, 2019, 63, 179-184.	1.1	12
125	Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1165-1170.	0.9	17
126	Genotypes and phenotypes of patients with Lafora disease living in Germany. Neurological Research and Practice, 2019, 1, .	1.0	6

#	Article	IF	Citations
127	Genotypes of amyotrophic lateral sclerosis in Mongolia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1300-1302.	0.9	1
128	An observational study on quality of life and preferences to sustain life in locked-in state. Neurology, 2019, 93, e938-e945.	1.5	41
129	Clinical and neuroimaging disparity between Chinese and German patients with cerebral small vessel disease: a comparative study. Scientific Reports, 2019, 9, 20015.	1.6	10
130	Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen. Frontiers in Neurology, 2019, 10, 1179.	1.1	18
131	InÂVivo Protein Complementation Demonstrates Presynaptic Î±-Synuclein Oligomerization and Age-Dependent Accumulation of 8â€“16-mer Oligomer Species. Cell Reports, 2019, 29, 2862-2874.e9.	2.9	26
132	Therapeutic advances in SMA. Current Opinion in Neurology, 2019, 32, 777-781.	1.8	8
133	Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial. EClinicalMedicine, 2019, 16, 98-106.	3.2	31
134	Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 4-10.	0.9	96
135	Non-invasive ventilation and hypercapnia-associated symptoms in amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 2019, 139, 128-134.	1.0	11
136	Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients. Journal of Neurology, 2019, 266, 183-194.	1.8	91
137	Association of NIPA1 repeat expansions with amyotrophic lateral sclerosis in a large international cohort. Neurobiology of Aging, 2019, 74, 234.e9-234.e15.	1.5	26
138	Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 157-164.	0.9	174
139	Moral judgment in patients with behavioral variant of frontotemporal dementia and amyotrophic lateral sclerosis: no impairment of the moral position, but rather its execution. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 12-18.	1.1	7
140	Cognitive and behavioral impairments in German and Chinese ALS populations â€“ a post-hoc comparison of national study data. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 28-36.	1.1	7
141	The applause sign in frontotemporal lobar degeneration and related conditions. Journal of Neurology, 2019, 266, 330-338.	1.8	15
142	Story of the ALS-FTD continuum retold: rather two distinct entities. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 586-589.	0.9	26
143	Analysis of CACNA1A CAG repeat lengths in patients with familialÂALS. Neurobiology of Aging, 2019, 74, 235.e5-235.e8.	1.5	6
144	Title is missing!. , 2019, 14, e0224331.		0

#	Article	IF	Citations
145	Title is missing!. , 2019, 14, e0224331.		0
146	Title is missing!. , 2019, 14, e0224331.		0
147	Title is missing!. , 2019, 14, e0224331.		0
148	Cognitive phenotypes of sequential staging in amyotrophic lateral sclerosis. Cortex, 2018, 101, 163-171.	1.1	46
149	The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy. Journal of Neurology, 2018, 265, 1026-1036.	1.8	29
150	Association of Serum Retinol-Binding Protein 4 Concentration With Risk for and Prognosis of Amyotrophic Lateral Sclerosis. JAMA Neurology, 2018, 75, 600.	4.5	24
151	Hot-spot KIF5A mutations cause familial ALS. Brain, 2018, 141, 688-697.	3.7	167
152	Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurobiology of Aging, 2018, 67, 21-22.	1.5	6
153	Comprehensive analysis of the mutation spectrum in 301 German ALS families. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 817-827.	0.9	80
154	Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany. Journal of Neurology, 2018, 265, 774-782.	1.8	31
155	Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 342-350.	1.1	33
156	Hyperconnective and hypoconnective cortical and subcortical functional networks in multiple system atrophy. Parkinsonism and Related Disorders, 2018, 49, 75-80.	1.1	23
157	Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis. Acta Neuropathologica, 2018, 135, 213-226.	3.9	97
158	Neuroprotective effect of acute ethanol intoxication in TBI is associated to the hierarchical modulation of early transcriptional responses. Experimental Neurology, 2018, 302, 34-45.	2.0	22
159	CHCHD10 mutations p.R15L and p.G66V cause motoneuron disease by haploinsufficiency. Human Molecular Genetics, 2018, 27, 706-715.	1.4	30
160	Alpha-synuclein is present in dental calculus but not altered in Parkinsonâ€™s disease patients in comparison to controls. Journal of Neurology, 2018, 265, 1334-1337.	1.8	1
161	A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. Alzheimer's Research and Therapy, 2018, 10, 41.	3.0	8
162	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, The, 2018, 17, 423-433.	4.9	342

#	Article	IF	Citations
163	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	3.8	517
164	Functional reorganization during cognitive function tasks in patients with amyotrophic lateral sclerosis. Brain Imaging and Behavior, 2018, 12, 771-784.	1.1	19
165	Fast progressive lower motor neuron disease is an ALS variant: A two-centre tract of interest-based MRI data analysis. NeuroImage: Clinical, 2018, 17, 145-152.	1.4	35
166	The fecal microbiome of ALS patients. Neurobiology of Aging, 2018, 61, 132-137.	1.5	102
167	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology, 2018, 90, e22-e30.	1.5	148
168	Imaging the pathoanatomy of amyotrophic lateral sclerosis in vivo: targeting a propagation-based biological marker. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 374-381.	0.9	74
169	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	0.9	89
170	Amyloid precursor protein-fragments-containing inclusions in cardiomyocytes with basophilic degeneration and its association with cerebral amyloid angiopathy and myocardial fibrosis. Scientific Reports, 2018, 8, 16594.	1.6	11
171	Endothelial damage, vascular bagging and remodeling of the microvascular bed in human microangiopathy with deep white matter lesions. Acta Neuropathologica Communications, 2018, 6, 128.	2.4	33
172	Cortico-efferent tract involvement in primary lateral sclerosis and amyotrophic lateral sclerosis: A two-centre tract of interest-based DTI analysis. NeuroImage: Clinical, 2018, 20, 1062-1069.	1.4	15
173	Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial. Lancet Neurology, The, 2018, 17, 1043-1052.	4.9	28
174	Corticoefferent pathology distribution in amyotrophic lateral sclerosis: in vivo evidence from a meta-analysis of diffusion tensor imaging data. Scientific Reports, 2018, 8, 15389.	1.6	23
175	Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 2018, 91, e1390-e1401.	1.5	85
176	Acute DWI Reductions In Patients After Single Epileptic Seizures - More Common Than Assumed. Frontiers in Neurology, 2018, 9, 550.	1.1	25
177	Screening for Cognitive Function in Complete Immobility Using Brainâ€“Machine Interfaces: A Proof of Principle Study. Frontiers in Neuroscience, 2018, 12, 517.	1.4	5
178	Identical patterns of cortico-efferent tract involvement in primary lateral sclerosis and amyotrophic lateral sclerosis: A tract of interest-based MRI study. NeuroImage: Clinical, 2018, 18, 762-769.	1.4	25
179	The Neuroprotective Effect of Ethanol Intoxication in Traumatic Brain Injury Is Associated with the Suppression of ErbB Signaling in Parvalbumin-Positive Interneurons. Journal of Neurotrauma, 2018, 35, 2718-2735.	1.7	14
180	Antisense oligonucleotides in neurological disorders. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641877693.	1.5	100

#	Article	IF	Citations
181	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients â€“ An Atlas-Based Volumetric MRI Study. Frontiers in Aging Neuroscience, 2018, 10, 45.	1.7	40
182	Longitudinal Diffusion Tensor Imaging Resembles Patterns of Pathology Progression in Behavioral Variant Frontotemporal Dementia (bvFTD). Frontiers in Aging Neuroscience, 2018, 10, 47.	1.7	13
183	Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Medizinische Genetik, 2018, 30, 252-258.	0.1	85
184	Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS. Cellular and Molecular Life Sciences, 2018, 75, 4301-4319.	2.4	34
185	Therapeutic decisions in ALS patients: cross-cultural differences and clinical implications. Journal of Neurology, 2018, 265, 1600-1606.	1.8	34
186	Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. Molecular Neurodegeneration, 2018, 13, 41.	4.4	77
187	Retinoids and Amyotrophic Lateral Sclerosisâ€”Reply. JAMA Neurology, 2018, 75, 1153.	4.5	0
188	NFâ€ºB activation in astrocytes drives a stageâ€specific beneficial neuroimmunological response in ALS. EMBO Journal, 2018, 37, .	3.5	108
189	Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2018, 17, 681-688.	4.9	51
190	Stage-dependent remodeling of projections to motor cortex in ALS mouse model revealed by a new variant retrograde-AAV9. ELife, 2018, 7, .	2.8	24
191	Experience matters: neurologistsâ€™ perspectives on ALS patientsâ€™ well-being. Journal of Neurology, 2017, 264, 639-646.	1.8	14
192	An eye-tracking controlled neuropsychological battery for cognitive assessment in neurological diseases. Neurological Sciences, 2017, 38, 595-603.	0.9	17
193	Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 208-216.	4.9	62
194	Predicting primary progressive aphasias with support vector machine approaches in structural MRI data. NeuroImage: Clinical, 2017, 14, 334-343.	1.4	42
195	Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis. Acta Neuropathologica, 2017, 133, 887-906.	3.9	111
196	Identifying ischemic stroke associated with cancer: a multiple model derived from a caseâ€“control analysis. Journal of Neurology, 2017, 264, 781-791.	1.8	19
197	Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology, 2017, 88, 961-969.	1.5	73
198	Predicting behavioral variant frontotemporal dementia with pattern classification in multi-center structural MRI data. NeuroImage: Clinical, 2017, 14, 656-662.	1.4	64

#	Article	IF	Citations
199	A first approach to a neuropsychological screening tool using eye-tracking for bedside cognitive testing based on the Edinburgh Cognitive and Behavioural ALS Screen. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 443-450.	1.1	15
200	Polyâ€<scp>GP</scp> in cerebrospinal fluid links C9orf72â€associated dipeptide repeat expression to the asymptomatic phase of <scp>ALS</scp>/<scp>FTD</scp>. EMBO Molecular Medicine, 2017, 9, 859-868.	3.3	90
201	An eye-tracker controlled cognitive battery: overcoming verbal-motor limitations in ALS. Journal of Neurology, 2017, 264, 1136-1145.	1.8	27
202	Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations. Annals of Neurology, 2017, 81, 837-848.	2.8	32
203	Association of Mutations in TBK1 With Sporadic and Familial Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. JAMA Neurology, 2017, 74, 110.	4.5	70
204	Genetic analysis of VCP and WASH complex genes in a German cohort of sporadic ALS-FTD patients. Neurobiology of Aging, 2017, 56, 213.e1-213.e5.	1.5	6
205	Intrinsic functional connectivity alterations in progressive supranuclear palsy: Differential effects in frontal cortex, motor, and midbrain networks. Movement Disorders, 2017, 32, 1006-1015.	2.2	24
206	Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1033-1041.	0.9	113
207	Genetic testing in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2017, 13, 262-263.	4.9	1
208	Epidemiology of amyotrophic lateral sclerosis in Southern Germany. Journal of Neurology, 2017, 264, 749-757.	1.8	72
209	Instability of C154Y variant of aldo-keto reductase 1C3. Chemico-Biological Interactions, 2017, 276, 194-202.	1.7	7
210	Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 256-264.	1.1	17
211	July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 471-474.	1.1	41
212	Edaravone: a baby in the bathwater?. Therapeutic Advances in Neurological Disorders, 2017, 10, 313-314.	1.5	2
213	Ribosomal transcription is regulated by PGC-1alpha and disturbed in Huntingtonâ€™s disease. Scientific Reports, 2017, 7, 8513.	1.6	31
214	Cortical influences drive amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 917-924.	0.9	152
215	The role of de novo mutations in the development of amyotrophic lateral sclerosis. Human Mutation, 2017, 38, 1534-1541.	1.1	13
216	Regional microstructural damage and patterns of eye movement impairment: a DTI and video-oculography study in neurodegenerative parkinsonian syndromes. Journal of Neurology, 2017, 264, 1919-1928.	1.8	13

#	Article	IF	Citations
217	Acute ethanol administration results in a protective cytokine and neuroinflammatory profile in traumatic brain injury. International Immunopharmacology, 2017, 51, 66-75.	1.7	28
218	Body weight is a robust predictor of clinical progression in Huntington disease. Annals of Neurology, 2017, 82, 479-483.	2.8	67
219	GFAP in early multiple sclerosis: A biomarker for inflammation. Neuroscience Letters, 2017, 657, 166-170.	1.0	45
220	Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis. Expert Review of Proteomics, 2017, 14, 769-777.	1.3	27
221	Adipokines, C-reactive protein and Amyotrophic Lateral Sclerosis â€“ results from a population- based ALS registry in Germany. Scientific Reports, 2017, 7, 4374.	1.6	45
222	Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 112-119.	1.1	63
223	The concept and diagnostic criteria of primary lateral sclerosis. Acta Neurologica Scandinavica, 2017, 136, 204-211.	1.0	32
224	Pathological TDP-43 changes in Betz cells differ from those in bulbar and spinal Î±-motoneurons in sporadic amyotrophic lateral sclerosis. Acta Neuropathologica, 2017, 133, 79-90.	3.9	68
225	ALS-causing mutations differentially affect PGC-1Î± expression and function in the brain vs. peripheral tissues. Neurobiology of Disease, 2017, 97, 36-45.	2.1	35
226	Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. International Journal of Stroke, 2017, 12, 985-990.	2.9	147
227	Impaired activation of ALS monocytes by exosomes. Immunology and Cell Biology, 2017, 95, 207-214.	1.0	39
228	Functional Connectivity Mapping in the Animal Model: Principles and Applications of Resting-State fMRI. Frontiers in Neurology, 2017, 8, 200.	1.1	78
229	Cerebral Microstructural Alterations after Radiation Therapy in High-Grade Glioma: A Diffusion Tensor Imaging-Based Study. Frontiers in Neurology, 2017, 8, 286.	1.1	15
230	Cardiac Findings in Amyotrophic Lateral Sclerosis: A Magnetic Resonance Imaging Study. Frontiers in Neurology, 2017, 8, 479.	1.1	18
231	Existential decision-making in a fatal progressive disease: how much do legal and medical frameworks matter?. BMC Palliative Care, 2017, 16, 80.	0.8	12
232	The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (Î±-syn) oligomerization and secretion. Aging, 2017, 9, 1677-1697.	1.4	7
233	Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2015-311387.	0.9	207
234	FUS Mislocalization and Vulnerability to DNA Damage in ALS Patients Derived hiPSCs and Aging Motoneurons. Frontiers in Cellular Neuroscience, 2016, 10, 290.	1.8	67

#	Article	IF	Citations
235	4-Aminopyridine Induced Activity Rescues Hypoexcitable Motor Neurons from Amyotrophic Lateral Sclerosis Patient-Derived Induced Pluripotent Stem Cells. Stem Cells, 2016, 34, 1563-1575.	1.4	109
236	TDPâ€43 loss of function inhibits endosomal trafficking and alters trophic signaling in neurons. EMBO Journal, 2016, 35, 2350-2370.	3.5	76
237	Functional connectivity changes resemble patterns of pTDP-43 pathology in amyotrophic lateral sclerosis. Scientific Reports, 2016, 6, 38391.	1.6	63
238	Modified serpinA1 as risk marker for Parkinsonâ€™s disease dementia: Analysis of baseline data. Scientific Reports, 2016, 6, 26145.	1.6	24
239	Age and education-matched cut-off scores for the revised German/Swiss-German version of ECAS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 374-376.	1.1	35
240	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 404-413.	1.1	84
241	Rare Variants in MME, Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal Polyneuropathies. American Journal of Human Genetics, 2016, 99, 607-623.	2.6	47
242	Medical decisions are independent of cognitive impairment in amyotrophic lateral sclerosis. Neurology, 2016, 87, 1737-1738.	1.5	25
243	Body fat distribution in Parkinson's disease: An MRI-based body fat quantification study. Parkinsonism and Related Disorders, 2016, 33, 84-89.	1.1	18
244	Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia. Cortex, 2016, 83, 124-135.	1.1	21
245	Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimerâ€²s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. Molecular and Cellular Proteomics, 2016, 15, 3126-3138.	2.5	92
246	Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Annals of Neurology, 2016, 79, 152-158.	2.8	188
247	Corticoefferent pathways in pure lower motor neuron disease: a diffusion tensor imaging study. Journal of Neurology, 2016, 263, 2430-2437.	1.8	30
248	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	9.4	494
249	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1037-1042.	9.4	218
250	Microstructure of the Midbrain and Cervical Spinal Cord in Idiopathic Restless Legs Syndrome: A Diffusion Tensor Imaging Study. Sleep, 2016, 39, 423-428.	0.6	14
251	Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis. Journal of Visualized Experiments, 2016, , .	0.2	5
252	LRRK2 contributes to monocyte dysregulation in Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2016, 4, 123.	2.4	29

#	Article	IF	Citations
253	Comment on â€œCutting Edge: Inhibiting TBK1 by Compound II Ameliorates Autoimmune Disease in Miceâ€• Journal of Immunology, 2016, 196, 530.1-531.	0.4	5
254	Towards a European Registry and Biorepository for Patients with Spinal and Bulbar Muscular Atrophy. Journal of Molecular Neuroscience, 2016, 58, 394-400.	1.1	10
255	Clinical Trials in Spinal and Bulbar Muscular Atrophyâ€”Past, Present, and Future. Journal of Molecular Neuroscience, 2016, 58, 379-387.	1.1	15
256	Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes. Acta Neuropathologica, 2016, 131, 379-391.	3.9	140
257	Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis. Brain, 2016, 139, 1106-1122.	3.7	80
258	Prophylactic antibiotics to reduce pneumonia after acute stroke. Lancet, The, 2016, 387, 432-433.	6.3	0
259	Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathologica, 2016, 132, 391-411.	3.9	116
260	NEK1mutations in familial amyotrophic lateral sclerosis. Brain, 2016, 139, e28-e28.	3.7	105
261	Status epilepticus: Clinical characteristics and EEG patterns associated with and without MRI diffusion restriction in 69 patients. Epilepsy Research, 2016, 120, 55-64.	0.8	44
262	Clinical features and differential diagnosis of flail arm syndrome. Journal of Neurology, 2016, 263, 390-395.	1.8	32
263	Serotonin 2B receptor slows disease progression and prevents degeneration of spinal cord mononuclear phagocytes in amyotrophic lateral sclerosis. Acta Neuropathologica, 2016, 131, 465-480.	3.9	41
264	A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 570-579.	0.9	138
265	Retinal involvement in amyotrophic lateral sclerosis: a study with optical coherence tomography and diffusion tensor imaging. Journal of Neural Transmission, 2016, 123, 281-287.	1.4	39
266	Screening forCHCHD10mutations in a large cohort of sporadic ALS patients: no evidence for pathogenicity of the p.P34S variant: Table 1. Brain, 2016, 139, e8-e8.	3.7	20
267	The association between alterations of eye movement control and cerebral intrinsic functional connectivity in Parkinsonâ€™s disease. Brain Imaging and Behavior, 2016, 10, 79-91.	1.1	36
268	Perception of Emotional Facial Expressions in Amyotrophic Lateral Sclerosis (ALS) at Behavioural and Brain Metabolic Level. PLoS ONE, 2016, 11, e0164655.	1.1	26
269	Telomere shortening leads to earlier age of onset in ALS mice. Aging, 2016, 8, 382-393.	1.4	31
270	Adipose Tissue Distribution in Patients withÂAlzheimerâ€™s Disease: A Whole Body MRI Case-Control Study. Journal of Alzheimer's Disease, 2015, 48, 825-832.	1.2	18

#	Article	IF	Citations
271	Profilin 1 with the amyotrophic lateral sclerosis associated mutation T109M displays unaltered actin binding and does not affect the actin cytoskeleton. BMC Neuroscience, 2015, 16, 77.	0.8	21
272	Histological characterization and biochemical analysis of paraspinal muscles in neuromuscularly healthy subjects. Muscle and Nerve, 2015, 52, 45-54.	1.0	7
273	Eye Movement Deficits Are Consistent with a Staging Model of pTDP-43 Pathology in Amyotrophic Lateral Sclerosis. PLoS ONE, 2015, 10, e0142546.	1.1	44
274	Î±-synuclein interacts with SOD1 and promotes its oligomerization. Molecular Neurodegeneration, 2015, 10, 66.	4.4	29
275	Internalized capillaries in skeletal muscle biopsy. Neuromuscular Disorders, 2015, 25, 94-95.	0.3	0
276	Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study. Journal of Neurology, 2015, 262, 849-858.	1.8	80
277	Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2015, 36, 2660.e15-2660.e20.	1.5	64
278	A revision of the El Escorial criteria - 2015. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 291-292.	1.1	373
279	The Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen: A cross-sectional comparison of established screening tools in a German-Swiss population. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 16-23.	1.1	109
280	Thiamine deficiency in amyotrophic lateral sclerosis: FigureÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1166-1168.	0.9	14
281	To rise and to fall: functional connectivity in cognitively normal and cognitively impaired patients with Parkinson's disease. Neurobiology of Aging, 2015, 36, 1727-1735.	1.5	119
282	Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nature Neuroscience, 2015, 18, 631-636.	7.1	652
283	Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase. Human Molecular Genetics, 2015, 24, 7390-7405.	1.4	84
284	TDP-43 is intercellularly transmitted across axon terminals. Journal of Cell Biology, 2015, 211, 897-911.	2.3	263
285	Super-Resolution Microscopy Reveals Presynaptic Localization of the ALS/FTD Related Protein FUS in Hippocampal Neurons. Frontiers in Cellular Neuroscience, 2015, 9, 496.	1.8	72
286	Communicating Hydrocephalus Following Eosinophilic Meningitis Is Pathogenic for Chronic Viliuisk Encephalomyelitis in Northeastern Siberia. PLoS ONE, 2014, 9, e84670.	1.1	8
287	Two-Point Magnitude MRI for Rapid Mapping of Brown Adipose Tissue and Its Application to the R6/2 Mouse Model of Huntington Disease. PLoS ONE, 2014, 9, e105556.	1.1	15
288	Elevated mRNA-levels of distinct mitochondrial and plasma membrane Ca2+ transporters in individual hypoglossal motor neurons of endstage SOD1 transgenic mice. Frontiers in Cellular Neuroscience, 2014, 8, 353.	1.8	16

#	Article	IF	Citations
289	Intrinsic Functional Connectivity Networks in Healthy Elderly Subjects: A Multiparametric Approach with Structural Connectivity Analysis. BioMed Research International, 2014, 2014, 1-14.	0.9	17
290	Amyotrophic lateral sclerosis: new ideas from cancer. Lancet Neurology, The, 2014, 13, 1067-1068.	4.9	3
291	Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study. Neurobiology of Aging, 2014, 35, 2420.e13-2420.e14.	1.5	16
292	FXN GAA repeat expansions in amyotrophic lateral sclerosis. Journal of Clinical Neuroscience, 2014, 21, 1319-1322.	0.8	0
293	Live and let die: existential decision processes in a fatal disease. Journal of Neurology, 2014, 261, 518-525.	1.8	49
294	Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathologica, 2014, 127, 423-439.	3.9	237
295	Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain, 2014, 137, 2938-2950.	3.7	91
296	Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain, 2014, 137, 1733-1740.	3.7	179
297	Two novel mutations in conserved codons indicate that CHCHD10 is a gene associated with motor neuron disease. Brain, 2014, 137, e309-e309.	3.7	101
298	Comment: Braak staging in clinical practice?. Neurology, 2014, 82, 862-862.	1.5	0
299	Polymerase chain reaction and Southern blot-based analysis of the C9orf72 hexanucleotide repeat in different motor neuron diseases. Neurobiology of Aging, 2014, 35, 1214.e1-1214.e6.	1.5	55
300	O1-09-04: ROLE OF FREE AND EXOSOMAL TDP-43 AS A DIAGNOSTIC TOOL IN NEURODEGENERATIVE DISEASES. , 2014, 10, P147-P147.		0
301	P2-054: DELETION OF 14-3-3GAMMA EXACERBATES DISEASE IN MOUSE MODELS OF NEURODEGENERATIVE PROTEINOPATHY. , 2014, 10, P490-P490.		0
302	Incidence and Geographical Variation of Amyotrophic Lateral Sclerosis (ALS) in Southern Germany â€“ Completeness of the ALS Registry Swabia. PLoS ONE, 2014, 9, e93932.	1.1	47
303	Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS) - registry Swabia. BMC Neurology, 2013, 13, 22.	0.8	30
304	Quality of life in fatal disease: the flawed judgement of the social environment. Journal of Neurology, 2013, 260, 2836-2843.	1.8	57
305	Amyotrophic lateral sclerosisâ€"a model of corticofugal axonal spread. Nature Reviews Neurology, 2013, 9, 708-714.	4.9	432
306	Stages of pTDPâ€43 pathology in amyotrophic lateral sclerosis. Annals of Neurology, 2013, 74, 20-38.	2.8	820

#	Article	IF	Citations
307	Oligodendroglia: new players in amyotrophic lateral sclerosis. Brain, 2013, 136, 370-371.	3.7	3
308	High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: A prospective interventional study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 533-536.	1.1	75
309	Adipose Tissue Distribution Predicts Survival in Amyotrophic Lateral Sclerosis. PLoS ONE, 2013, 8, e67783.	1.1	74
310	Amyotrophic lateral sclerosis. Current Opinion in Neurology, 2012, 25, 530-535.	1.8	85
311	Neuroimaging of motor neuron diseases. Therapeutic Advances in Neurological Disorders, 2012, 5, 119-127.	1.5	29
312	A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e37885.	1.1	125
313	Emotional adjustment in amyotrophic lateral sclerosis (ALS). Journal of Neurology, 2012, 259, 334-341.	1.8	54
314	Accelerated aging phenotype in mice with conditional deficiency for mitochondrial superoxide dismutase in the connective tissue. Aging Cell, 2011, 10, 912-912.	3.0	4
315	Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurology, The, 2011, 10, 75-82.	4.9	457
316	Stability effects on results of diffusion tensor imaging analysis by reduction of the number of gradient directions due to motion artifacts: an application to presymptomatic Huntingtonâ€™s disease. PLOS Currents, 2011, 3, RRN1292.	1.4	19
317	Response to Letter Regarding Article, â€œCardiomyopathy in a Duchenne Muscular Dystrophy Carrier and Her Diseased Son: Similar Pattern Revealed by Cardiovascular MRIâ€. Circulation, 2010, 122, .	1.6	0
318	Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 38-45.	2.3	293
319	Review: Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials. Therapeutic Advances in Neurological Disorders, 2009, 2, 319-326.	1.5	31
320	Neuromuscular diseases: new hopes for alleviation and elimination. Lancet Neurology, The, 2009, 8, 16-17.	4.9	5
321	Intersubject variability in the analysis of diffusion tensor images at the group level: fractional anisotropy mapping and fiber tracking techniques. Magnetic Resonance Imaging, 2009, 27, 324-334.	1.0	41
322	MRI-based functional neuroimaging in ALS: An update. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 258-268.	2.3	40
323	Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 217-223.	2.3	98
324	Diffusion tensor imaging and tractwise fractional anisotropy statistics: quantitative analysis in white matter pathology. BioMedical Engineering OnLine, 2007, 6, 42.	1.3	53

#	Article	IF	Citations
325	Matrix metalloproteinasesâ€"A conceptional alternative for disease-modifying strategies in ALS/MND?. Experimental Neurology, 2006, 201, 277-280.	2.0	11
326	Severity of Depressive Symptoms and Quality of Life in Patients with Amyotrophic Lateral Sclerosis. Neurorehabilitation and Neural Repair, 2005, 19, 182-193.	1.4	133
327	Preclinical Trials â€" An Update on Translational Research in ALS. Neurodegenerative Diseases, 2005, 2, 215-219.	0.8	11
328	Mechanisms of Disease: Motoneuron Disease Aggravated by Transgenic Expression of a Functionally Modified AMPA Receptor Subunit. Annals of the New York Academy of Sciences, 2005, 1053, 269-286.	1.8	5
329	Imaging of activated microglia with PET and [11 C]PK 11195 in corticobasal degeneration. Movement Disorders, 2004, 19, 817-821.	2.2	39
330	Measures of Quality of Life: Pro. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, S19-S19.	1.4	0
331	Superoxide dismutase mutations of familial amyotrophic lateral sclerosis and the oxidative inactivation of calcineurin. FEBS Letters, 2001, 503, 201-205.	1.3	17
332	A novel calcineurin splice variant that modifies calcineurin activity. FEBS Journal, 2001, 268, 5955-5960.	0.2	6
333	Recessively inherited amyotrophic lateral sclerosis: a German family with the D90A CuZn-SOD mutation. Journal of Neurology, 2000, 247, 783-786.	1.8	7
334	FTDP-17: An early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Annals of Neurology, 1999, 46, 708-715.	2.8	190
335	NEUROTOXIC MECHANISMS OF DEGENERATION IN MOTOR NEURON DISEASES*. Drug Metabolism Reviews, 1999, 31, 619-634.	1.5	7
336	Lack of association of apolipoprotein E Ïµ4 allele with bulbar-onset motor neuron disease. Annals of Neurology, 1997, 41, 417-417.	2.8	19
337	Multimodal inÂvivo staging in amyotrophic lateral sclerosis using artificial intelligence. Annals of Clinical and Translational Neurology, 0, , .	1.7	5
338	Predictive parameters of early respiratory decline in Amyotrophic Lateral Sclerosis. European Journal of Neurology, 0, , .	1.7	3